Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

2231 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

2231 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Oncology
Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment
What is being tested: Apixaban (an oral anticoagulant) versus standard care to evaluate its effectiveness in preventing venous thromboembolism (VTE) in ambulatory patients with…
28 Sep 2026 NCT07160686
● Recruiting Phase III Oncology
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Being tested: Ersodetug as an add-on therapy to standard care for managing hypoglycemia in patients with Tumor Hyperinsulinism, with evaluation of glycemic control, safety,…
28 Sep 2026 NCT06881992
active not recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
A trial testing whether rozanolixizumab safely and effectively treats adults with MOG antibody-associated nerve inflammation.
25 Sep 2026 NCT05063162
active not recruiting Phase III
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
New drug talquetamab combined with daratumumab tested against standard treatment in relapsed/resistant myeloma patients.
25 Sep 2026 NCT05455320
● Recruiting Phase III
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Xeomin injections into head and neck muscles tested against placebo to reduce monthly migraine days in episodic migraine sufferers.
25 Sep 2026 NCT07018700
active not recruiting Phase III
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
CAR-T cell therapy (cilta-cel) added to standard chemotherapy improves survival without transplant in newly diagnosed myeloma patients.
25 Sep 2026 NCT04923893
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
What is being tested: Safety comparison of two propellant formulations in metered dose inhalers (MDIs) over 4 weeks exposure—HFA-152a (test propellant) versus HFA-134a (established…
25 Sep 2026 NCT07645248
● Recruiting Phase III Oncology
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
What is being tested: Ramantamig plus daratumumab (a novel combination) is being compared against two standard treatment regimens (DVRd or DRd) in newly diagnosed…
25 Sep 2026 NCT07665450
● Recruiting Phase II / Phase III
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Comparing two growth-boosting drugs (BMN 333 and vosoritide) in children with achondroplasia to see which works better and is safer.
24 Sep 2026 NCT07441876
● Recruiting Phase III Cardiology / Cardiovascular
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
What is being tested: A fixed-dose combination of balcinrenone (a non-steroidal mineralocorticoid receptor antagonist) plus dapagliflozin (SGLT2 inhibitor) versus dapagliflozin alone in patients with…
24 Sep 2026 NCT07624305
● Recruiting Phase III Dermatology
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Trial testing weekly marstacimab injections in children with haemophilia A or B to assess safety and bleeding prevention.
23 Sep 2026 NCT05611801
active not recruiting Phase III Oncology
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Pirtobrutinib versus standard BTK inhibitors for mantle cell lymphoma treatment comparison.
23 Sep 2026 NCT04662255
active not recruiting Phase III
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Efgartigimod injections under the skin improved platelet counts in adults with immune thrombocytopenia, showing good safety.
23 Sep 2026 NCT04812925
● Recruiting Phase II / Phase III Oncology
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
Trial testing a new antibody drug combined with chemotherapy to treat high-risk neuroblastoma in young children.
23 Sep 2026 NCT07549321
● Recruiting Phase III Respiratory / COPD / Asthma
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
Treatment being tested: Nerandomilast, a novel therapeutic agent, is being investigated for its efficacy in slowing disease progression in fibrosing interstitial lung disease (excluding…
23 Sep 2026 NCT07540988
● Recruiting Phase III Diabetes / Metabolic
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Treatment being tested: AZD6234, a novel investigational agent, is being evaluated for its efficacy and safety in reducing body weight compared to placebo over…
22 Sep 2026 NCT07784270
● Recruiting Phase III Oncology
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
What is being tested: Setidegrasib, a KRAS inhibitor, combined with either mFOLFIRINOX or NALIRIFOX chemotherapy regimens in patients with metastatic pancreatic cancer to evaluate…
22 Sep 2026 NCT07409272
active not recruiting Phase III
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Erenumab reduced monthly migraine days more than placebo in children and teenagers aged 6-17 with episodic migraines.
21 Sep 2026 NCT03836040
active not recruiting Phase III Rheumatology
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Trial testing JNJ-77242113 against placebo and deucravacitinib for moderate to severe plaque psoriasis effectiveness.
21 Sep 2026 NCT06143878
● Recruiting Phase III Rare Diseases
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
Gene therapy for inherited eye disease causing vision loss in males, testing safety and effectiveness in children and adults.
21 Sep 2026 NCT05878860
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
Treatment being tested: Lunsekimig, a novel therapeutic agent being evaluated for long-term safety and efficacy in adults with eosinophilic COPD that remains inadequately controlled…
21 Sep 2026 NCT07793409
● Recruiting Phase III
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Elritercept versus epoetin alfa for reducing blood transfusion needs in low-risk myelodysplastic syndrome anaemia.
18 Sep 2026 NCT07422480
● Recruiting Phase II / Phase III Infectious Disease
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
PLG0206 tested as wound irrigation during knee implant infection surgery to prevent reinfection and improve outcomes.
17 Sep 2026 NCT07214311
active not recruiting Phase III
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Elamipretide daily injections slow photoreceptor loss in dry age-related macular degeneration compared with placebo.
17 Sep 2026 NCT06373731
● Recruiting Phase III
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Long-term safety and effectiveness of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal haemoglobinuria.
17 Sep 2026 NCT05744921
● Recruiting Phase III Cardiology / Cardiovascular
Low INR to Minimize Bleeding With Mechanical Valves Trial
What is being tested: The safety and efficacy of a lower INR target range (1.5-2.5) compared to standard anticoagulation in patients with mechanical bileaflet…
17 Sep 2026 NCT03636295
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Trial comparing divarasib to sotorasib/adagrasib for treating advanced lung cancer with KRAS G12C mutation in previously treated patients.
16 Sep 2026 NCT06497556
● Recruiting Phase III Mental Health / Psychiatry
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
KarXT may help prevent relapse in schizophrenia patients already responding to treatment.
14 Sep 2026 NCT07686263
● Recruiting Phase III Oncology
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Trial comparing subcutaneous versus intravenous tislelizumab plus chemotherapy for advanced gastric cancer in 351 patients.
14 Sep 2026 NCT07043400
● Recruiting Phase III Respiratory / COPD / Asthma
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease
Treatment being tested: Trontinemab, a monoclonal antibody targeting Alzheimer's disease pathology, is being evaluated in cognitively unimpaired individuals with biomarker evidence of AD pathology…
10 Sep 2026 NCT07717411
● Recruiting Phase III Diabetes / Metabolic
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
What is being tested: AZD6234 as an adjunctive treatment to incretin-based therapies, with efficacy measured by percentage body weight change from baseline over 68…
10 Sep 2026 NCT07776509
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
What is being tested: Intranasal cenegermin (a recombinant human nerve growth factor) versus vehicle control to assess efficacy and safety in treating non-arteritic anterior…
10 Sep 2026 NCT07453888
active not recruiting Phase III Diabetes / Metabolic
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Semaglutide weekly injections help children and teenagers lose weight better than placebo, alongside lifestyle support.
09 Sep 2026 NCT05726227
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
What is being tested: Elecoglipron, a novel therapeutic agent, is being evaluated against placebo for its effects on cardiovascular outcomes in patients with HFpEF…
09 Sep 2026 NCT07761117
● Recruiting Phase III Diabetes / Metabolic
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
What is being tested: Elecoglipron (a novel therapeutic agent) versus placebo in adults with chronic kidney disease, with or without type 2 diabetes, all…
09 Sep 2026 NCT07753993
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Being tested: Long-term safety and efficacy of belimumab (a B-lymphocyte stimulator inhibitor) in adults with interstitial lung disease associated with systemic sclerosis and other…
09 Sep 2026 NCT06716606
● Recruiting Phase III Cardiology / Cardiovascular
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
What is being tested: IgPro20 (immunoglobulin replacement therapy) efficacy, safety, and pharmacokinetics in adults with secondary immune deficiencies resulting from B-cell targeting CAR T-cell…
09 Sep 2026 NCT07648264
● Recruiting Phase III Oncology
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
What is being tested: Precemtabart tocentecan (Precem-TcT), administered with or without bevacizumab, is being compared against the standard treatment of trifluridine/tipiracil plus bevacizumab in…
09 Sep 2026 NCT07549412
● Recruiting Phase III Oncology
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
What is being tested: Sonesitatug vedotin (an antibody-drug conjugate targeting Claudin18.2) combined with capecitabine, with or without rilvegostomig (an ADAM10 inhibitor), as first-line treatment…
09 Sep 2026 NCT07431281
● Recruiting Phase III Respiratory / COPD / Asthma
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
What is being tested: Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), is being evaluated for its efficacy and safety in treating interstitial lung…
08 Sep 2026 NCT06572384
active not recruiting Phase III Oncology
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Adding talazoparib to enzalutamide improves outcomes in men with metastatic prostate cancer and DNA repair gene mutations.
04 Sep 2026 NCT04821622
active not recruiting Phase III
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
Adding tafasitamab to standard lymphoma treatment improves outcomes in patients with relapsed or refractory follicular or marginal zone lymphoma.
04 Sep 2026 NCT04680052
● Recruiting Phase III
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
Depemokimab added to standard care reduced flares in adults with uncontrolled hypereosinophilic syndrome over 52 weeks.
04 Sep 2026 NCT05334368
● Recruiting Phase III
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Study comparing NXT007 with emicizumab for preventing bleeding in hemophilia A patients aged 12 and over.
04 Sep 2026 NCT07416604
● Recruiting Phase III Oncology
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
What is being tested: This phase 3 trial evaluates whether lower doses of Androgen Receptor Pathway Inhibitors (ARPIs) can achieve equivalent clinical effectiveness compared…
04 Sep 2026 NCT07751133
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Adding immunotherapy to standard HER2 treatment reduces breast cancer recurrence risk in patients with residual disease after pre-surgery therapy.
03 Sep 2026 NCT04873362
active not recruiting Phase III Oncology
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Trial testing combination immunotherapy plus targeted drugs for untreated advanced melanoma with BRAF mutations.
03 Sep 2026 NCT04657991
● Recruiting Phase III
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
A trial testing a new drug called atumelnant in adults with a genetic condition affecting the adrenal glands to check if it works, is…
02 Sep 2026 NCT07144163
active not recruiting Phase III Oncology
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Adding quemliclustat to standard chemotherapy did not improve survival in advanced pancreatic cancer compared to chemotherapy alone.
02 Sep 2026 NCT06608927
active not recruiting Phase III
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Trial comparing subcutaneous versus intravenous isatuximab combined with pomalidomide and dexamethasone in relapsed multiple myeloma.
02 Sep 2026 NCT05405166